Calibrate vs. Embody: prices, fine print, and the honest verdict

Tirzepatide pricing

Calibrate offers tirzepatide without a published price we could capture. Embody carries only a reported figure — $99/mo from a competing comparison site (May 2026), never captured on a provider page — so it is listed, reviewed, and excluded from ranked comparisons pending verification.

Different products, not just different prices

Calibrate fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while Embody sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

Calibrate: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. Embody: Third-party-reported; dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Calibrate: annual program; program terms apply. Embody: terms not published.

The five normalizations, applied to this pair

1 · All-in, not advertised. Calibrate bills at manufacturer/insurance rates plus any stated program fee; Embody's reported $99 can't be normalized because no source page confirms what it includes. 4 · Evidence tiered. Calibrate: no price published, read 2026-08-05; Embody: third-party-reported. 5 · Pharmacy weighed. Calibrate names no pharmacy; Embody names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Calibrate: no membership — the medication figure is the billed figure; program terms apply; commitment: annual program. Embody: no membership — the medication figure is the billed figure. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Calibrate carries no price published pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Embody carries third-party-reported pricing; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Calibrate: shipping per pharmacy; consultation program-based coaching; video visit model. Embody: shipping, consult, and refill logistics aren’t published in our capture — ask at intake, in writing. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Calibrate if only the FDA-approved product will do; you want the insurance paperwork done for you. Pick Embody if its published terms happen to fit your state, format, or timing. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Calibrate, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. For Embody, ranking would require: a provider-page capture confirming the reported $99 figure and exactly what it includes; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Widen the frame one step and the strongest adjacent options are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

This one is a product decision more than a price decision — cheapest-possible compounded versus FDA-approved brand. Both records, with dates and sources, live in the pricing database.